Windlas Biotech Ltd Financials
Company Logo

Windlas Biotech Ltd Financial Statement

Windlas Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue191.84
Operating Expense163.95
Net Profit15.66
Net Profit Margin8.16
Earning Per Share7.49
EBIDTA28.39
Effective Tax Rate18.39
Invest in Windlas Biotech Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Windlas Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual630.96
Operating Expenses Annual552.85
Operating Profit Annual91.57
Interest Annual1.10
Depreciation13.20
Net Profit Annual58.14
Tax Annual18.88

Windlas Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning3.69
Cash Flow from Operations108.91
Cash Flow from Investing-92.07
Cash Flow from Financing-15.29
Cash Flow at the End5.24

Windlas Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)14.51
PBIT Margin (%)12.38
PBT Margin (%)1.12
Net PROFIT Margin (%)9.21
Return On Networth / Equity (%)13.63
Return On Networth /Employed (%)18.03
Return On Assets (%)13.45
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)1.46

Windlas Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual179.05
Total Current Assets Annual431.24
Non Current Assets Annual194.92
Total Shareholders Funds Annual450.29
Total Assets Annual626.16

Windlas Biotech Ltd Earning Calls

EPS (INR)

Expected

7.49

Reported

7.49

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.31%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 30, 2024, Windlas Biotech Ltd has a market capitalization of 1,065.61 Cr. Value Research classifies it as a Small-Cap company.
Yes, Windlas Biotech Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Windlas Biotech Ltd recorded a total revenue of approximately 630.96 Cr marking a significant milestone in the company's financial performance.
Windlas Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.2% annually, respectively..
Windlas Biotech Ltd's current PE ratio is 18.33.
Windlas Biotech Ltd's ROCE averaged 14.4% from the FY ending March 2022 to 2024, with a median of 14.2%. It peaked at 17.2% in March 2024, reflecting strong capital efficiency over the period..
Windlas Biotech Ltd's latest EBIT is Rs. 78.12 Cr, surpassing the average EBIT of Rs. 61.14 Cr over the 5 years..